What is the current stock price of LakeShore Biopharma Co., Ltd (LSB)?

As of the latest market data, LakeShore Biopharma Co., Ltd (LSB) is trading at $0.63. The stock has seen a loss of 0.00% today.

Does LakeShore Biopharma Co., Ltd (LSB) pay a dividend?

Based on current data, LakeShore Biopharma Co., Ltd does not have a confirmed active dividend policy.

What is the market cap of LakeShore Biopharma Co., Ltd?

The current market capitalization of LakeShore Biopharma Co., Ltd (LSB) is approximately unavailable.

LSB

LakeShore Biopharma Co., Ltd·Healthcare

0.63

0.000%(+0.00)

Close Price

0.54

13.892%(−0.09)

After Hours

Last Updated: — ET

52W L: $0.5752W H: $8.60

LSB NEWS

businesswire.com

May 19

LSB Industries Reaches Agreement Establishing a Pathway to 100% Ownership of El Dorado CCS Project

OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (NYSE: LXU) (“LSB” or “the Company”), today announced that it has reached an agreement with Lapis Carbon Solutions (“Lapis”) that establishes a strategic pathway for LSB to take full ownership of Project Blue, the carbon capture and sequestration (“CCS”) project currently underway at its El Dorado, Arkansas facility (“the Project”). “The opportunity to achieve full ownership of this project is an important strategic step for the Company,” sai.

globenewswire.com

May 8

LSBCF Investors Have Opportunity to Join LakeShore Biopharma Co., Ltd Fraud Investigation with the Schall Law Firm

LOS ANGELES, May 08, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of LakeShore Biopharma Co., Ltd (“LakeShore Biopharma” or “the Company”) (OTC: LSBCF) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

businesswire.com

Apr 29

LSB Industries, Inc. Reports Operating Results for the 2026 First Quarter

OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (NYSE: LXU) (“LSB,” “we,” “us,” “our,” or the “Company”) today announced results for the first quarter ended March 31, 2026. First Quarter 2026 Results and Recent Highlights Net sales of $169.5 million compared to $143.4 million in the first quarter of 2025 Net income of $19.7 million compared to a net loss of $1.6 million in the first quarter of 2025 Diluted EPS of $0.27 compared to $(0.02) for the first quarter of 2025 Adjusted EBITDA(1) of.

businesswire.com

Apr 15

LSB Industries, Inc. Schedules 2026 First Quarter Results Release for Wednesday, April 29th and Conference Call for Thursday, April 30th

OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (“LSB”) (NYSE: LXU), today announced that it will release its financial results for the first quarter ended March 31, 2026 on April 29, 2026 after the close of the stock market. LSB's management will host a conference call on Thursday, April 30, 2026 at 10:00 am ET / 9:00 am CT to discuss these results. Participating in the call will be Chairman & Chief Executive Officer, Mark Behrman, Executive Vice President & Chief Financial Office.

businesswire.com

Apr 2

LSB Industries, Inc. Appoints Jonathan Ackerman as an Independent Member of the Board of Directors; Announces Retirement of Steve Packebush

OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (“LSB” or “the Company”), (NYSE: LXU) today announced that it has appointed Jonathan Z. Ackerman as an independent member of the Board of Directors (the “Board”) effective April 2, 2026. Mr. Ackerman will stand for direct election by shareholders for the first time at the annual meeting of stockholders on May 21, 2026 (the “2026 Annual Meeting”). Mr. Ackerman has a lengthy track record as a successful leader in infrastructure development and.

prnewswire.com

Mar 25

LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company

BEIJING, March 25, 2026 /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("LakeShore Biopharma" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the special committee of its board of directors (the "Special Committee") has received a revised preliminary non-binding proposal letter (the "Proposal Letter"), dated March 24, 2026, from Oceanpine Skyline Inc. ("Parent") and Oceanpine Merger Sub Inc. ("Merger Sub"), to reduce the purchase price for acquiring all of the outstanding ordinary shares of the Company (the "Ordinary Shares") that are not currently owned by Parent, Merger Sub, the Rollover Shareholders (as defined in the Agreement and Plan of Merger, dated November 4, 2025, by and among the Company, Parent and Merger Sub), or their respective affiliates, to US$0.06 per Ordinary Share (the "Proposed Transaction"). A copy of the Proposal Letter is attached hereto as Exhibit A.

Company Profile

LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 2002 and is based in Beijing, China.

Sector

Healthcare

Industry

Biotechnology

Employees

758

IPO Date

2021-08-05

Beta

0.57

Websitewww.ysbiopharm.com↗